Abstract
A case of neuroleptic malignant syndrome (NMS) in a patient with Parkinson's disease (PD) is presented. The syndrome was precipitated by the atypical antipsychotic, ziprasidone. The challenge of recognizing NMS in a patient with underlying parkinsonian symptoms, where prominent symptom overlap can occur, is discussed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 205-207 |
| Number of pages | 3 |
| Journal | Human Psychopharmacology |
| Volume | 19 |
| Issue number | 3 |
| DOIs | |
| State | Published - Apr 2004 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Neurology
- Clinical Neurology
- Psychiatry and Mental health
- Pharmacology (medical)
Fingerprint
Dive into the research topics of 'Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson's disease: A diagnostic challenge'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver